As Global Protein Supplement Market Already Topping $20.4 Billion, Annually, PROTEINnMORE^™ Enters Market With State-of-the-art Supplement

Las Vegas, NV - (NewMediaWire) - December 01, 2022 - BioAdaptives Inc. (OTC BDPT) continues to expand the Company’s inventory of products with the launch of PROTEINnMORE^™ an advanced bodybuilding, plant-based supplement designed to improve muscle growth and strength.  PROTEINnMORE^™ provides not only a balanced blend of plant-based protein but also ingredients that enhance blood flow and muscle function.  A recent market research summary estimates, “The global protein supplements market size was valued at USD 20.47 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2021 to 2030. The U.S. was the largest market in the North American region for protein supplements, with total revenue of USD 8.44 billion in 2021.” (grandviewresearch.com)

The Company developed and test marketed this formulation, based on Traditional Chinese Medicine and Ayurvedic Culture, in response to the strong demand for a premium, vegan-friendly product that promotes optimal fitness and peak physical performance.  

Edward Jacobs, M.D., BioAdaptives CEO, states “PROTEINnMORE^™, an all-natural, gluten-free, non-gmo supplement formulation, is designed to achieve and maintain top physical performance. PROTEINnMORE^™is blended, purified hemp seed and pea protein combined with spirulina and other all natural ingredients that maximize gastrointestinal uptake and bioavailability of nutrients, including essential amino acids.  In addition, this unique protein blend is formulated to promote muscle power by directly increasing contractility of muscle fibers. The superior quality ingredients are selected for their individual beneficial effects and for their expected synergistic features including important anti-inflammatory and antioxidant activities. Based on initial reports and marketing research, including increasing demand from the athletic and fitness infrastructure with higher disposable income, we expect that PROTEINnMORE^™ will be one of our most popular supplement formulas.”       

About BioAdaptives, Inc.

BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity and immune system defense; resistance to stress; endurance; recovery from injury, illness and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best worldwide sources and utilize proprietary methods of enhancing the bioavailability of nutrients. The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. Our current product line includes PrimiLungs™ and PluriPain® for humans and Equine All-in-One™ for horses. Additional human products, to be introduced soon, are designed to aid memory, cognition and focus; assist in sleep and fatigue reduction; and improve overall emotional and physical wellness. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.”

Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Contact:

Investor Relations

BioAdaptives, Inc.

(702) 659-8829

info@bioadaptives.com

View the original release on www.newmediawire.com